Список проголосовавших за комментарий " On The Wires<ul><li>Kura Oncology, Inc. (<strong>KURA</strong>) announced an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017), taking place March 6-8, 2017 in Paris, France. The presentation will feature clinical data from the first stage of Kura Oncology's tipifarnib Phase 2 program in HRAS mutant tumors.</li><li>China Lodging Group, Limited (<strong>HTHT</strong>) announced that its wholly-owned subsidiary China Lodging Holdings (<strong>HK</strong>) Limited has entered into a definitive share purchase agreement with the shareholders of Crystal Orange Hotel Holdings Limited to acquire all of the equity interests of Crystal Orange for an initial aggregate consideration in cash of approximately RMB 3.65 billion, with customary post-closing adjustments. The closing of the Transaction is subject to the approval from the Antitrust Bureau of Ministry of Commerce of China.</li><li>HTG Molecular Diagnostics (<strong>HTGM</strong>) announced that its new direct-target sequencing chemistry will be available in the company's VERI/O laboratory as a service offering beginning in the first quarter of 2017. The new chemistry is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company's current HTG EdgeSeq chemistry applications. The initial panel planned for the VERI/O laboratory will detect common mutations in the EGFR, KRAS and BRAF genes for retrospective research studies especially from small and difficult samples, such as formalin-fixed, paraffin-embedded tissue.</li><li>Five Star Quality Care (<strong>FVE</strong>) announced that it will issue a press release containing its fourth quarter and year end 2016 financial results before the Nasdaq opens on Friday, March 3, 2017. At 10:00 a.m. Eastern Time that morning, President and Chief Executive Officer Bruce Mackey, Chief Financial Officer and Treasurer Rick Doyle and Chief Operating Officer Scott Herzig will host a conference call to discuss these results.</li><li>Recro Pharma (<strong>REPH</strong>) announced completion of enrollment for its double-blind Phase III safety study evaluating the safety and tolerability of intravenous (IV) meloxicam (N1539) following major surgery. </li></ul>"